Portal de Periódicos da CAPES

Association of Gadolinium Based Magnetic Resonance Imaging Contrast Agents and Nephrogenic Systemic Fibrosis

2008; Lippincott Williams & Wilkins; Volume: 180; Issue: 3 Linguagem: Inglês

10.1016/j.juro.2008.05.005

1527-3792

Gautam Bhave, Julia B. Lewis, Sam S. Chang,

MRI in cancer diagnosis

No AccessJournal of UrologyReview Article1 Sep 2008Association of Gadolinium Based Magnetic Resonance Imaging Contrast Agents and Nephrogenic Systemic Fibrosis Gautam Bhave, Julia B. Lewis, and Sam S. Chang Gautam BhaveGautam Bhave Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee , Julia B. LewisJulia B. Lewis Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee , and Sam S. ChangSam S. Chang Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee View All Author Informationhttps://doi.org/10.1016/j.juro.2008.05.005AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We investigated the recently discovered association between gadolinium based magnetic resonance imaging contrast agents and the development of nephrogenic systemic fibrosis in patients with chronic kidney disease or acute kidney injury. Materials and Methods: A systematic review of the PubMed® database and publicly available patient databases was performed to characterize nephrogenic systemic fibrosis and its possible association with exposure to gadolinium based magnetic resonance imaging contrast agents. Results: Data from case series reports, nephrogenic systemic fibrosis patient databases, nephrogenic systemic fibrosis case reporting to the Food and Drug Administration after gadolinium contrast agent exposure and retrospective case control studies suggest a strong association between the use of gadolinium based magnetic resonance imaging contrast agents and the subsequent development of nephrogenic systemic fibrosis in patients with renal disease. These data also suggest that the risk of nephrogenic systemic fibrosis depends on the degree of renal dysfunction, dose of contrast agent, gadolinium contrast agent stability and severity of concomitant illness. Thus, the occurrence of nephrogenic systemic fibrosis after gadolinium contrast agent exposure may vary from negligible up to 2% to 5% in select high risk clinical situations. Conclusions: Magnetic resonance imaging using gadolinium based contrast agents must be performed judiciously in patients with renal dysfunction, carefully weighing on a case by case basis the benefits of magnetic resonance imaging and the risk of nephrogenic systemic fibrosis as well as the disadvantages of undergoing alternative or foregoing imaging studies. References 1 : Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet2000; 356: 1000. Google Scholar 2 : Nephrogenic fibrosing dermopathy. Am J Dermatopathol2001; 23: 383. Google Scholar 3 : Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial2006; 19: 191. Google Scholar 4 : Gadolinium and nephrogenic systemic fibrosis. Kidney Int2007; 72: 260. Google Scholar 5 : New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol2007; 18: 2636. Google Scholar 6 : Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol2003; 139: 903. Google Scholar 7 : Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol2006; 45: 56. Google Scholar 8 : Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol2003; 48: 55. Google Scholar 9 : Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med2003; 114: 563. Google Scholar 10 : http://www.icnfdr.org. Accessed October 24, 2007. Google Scholar 11 : Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology2007; 243: 148. Google Scholar 12 U.S. Food and Drug Administration: Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans. 2006. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200612HCP.htm. Accessed October 24, 2007. Google Scholar 13 Pharmacovigilance Working Party: Increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. 2007. http://www.ismrm.org/special/MHRA_Report.pdf. Accessed November 18, 2007. Google Scholar 14 : Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant2006; 21: 1104. Google Scholar 15 : Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol2007; 188: 586. Google Scholar 16 : Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep2007; 56: 137. Google Scholar 17 : Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol2006; 17: 2359. Google Scholar 18 : Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol2007; 2: 264. Google Scholar 19 : Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant2007; 7: 2425. Google Scholar 20 : Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology2007; 245: 168. Google Scholar 21 : Nashville, TN: Frost and Sullivan, Vanderbilt University Walker Library2007. http://www.frost.com. Published June 25, Accessed November 2, 2007. Google Scholar 22 : Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant2007; 22: 3174. Google Scholar 23 : MR-angiography: the role of contrast agents. Eur J Radiol2000; 34: 247. Google Scholar 24 : 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm. Accessed October 24, 2007. Google Scholar 25 : Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol2006; 20: 563. Google Scholar 26 : Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol1998; 5: 491. Google Scholar 27 : Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol2007; 80: 73. Google Scholar 28 : Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol2007; 56: 27. Google Scholar 29 : Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol2007; 56: 21. Google Scholar 30 : Off-label use and reimbursement of contrast media in MR. J Magn Reson Imaging1999; 10: 489. Google Scholar 31 : Bracco reports case of NSF with gadolinium contrast agent ProHance: Diagnostic Imaging. 2007. http://www.dimag.com/showNews.jhtml?articleID=201802091. Accessed November 18, 2007. Google Scholar 32 : Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol2007; 57: 725. Google Scholar 33 : Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med2007; 357: 720. Google Scholar 34 : Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol2001; 42: 339. Google Scholar 35 : Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?". AJR Am J Roentgenol2007; 189: W234. Google Scholar 36 : ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol2007; 188: 1447. Google Scholar 37 : A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol2004; 44: 1393. Google Scholar 38 : Clinical practice: Preventing nephropathy induced by contrast medium. N Engl J Med2006; 354: 379. Google Scholar 39 : Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA2004; 291: 2328. Google Scholar 40 : The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant2006; 21: i2. Google Scholar 41 : Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am2003; 30: 499. Google Scholar 42 : How I do it: evaluating renal masses. Radiology2005; 236: 441. Google Scholar 43 : Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol2007; 188: 563. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetails Volume 180Issue 3September 2008Page: 830-835 Advertisement Copyright & Permissions© 2008 by American Urological AssociationKeywordskidney diseasesgadoliniummagnetic resonance imagingMetricsAuthor Information Gautam Bhave Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee Nothing to disclose. More articles by this author Julia B. Lewis Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee Nothing to disclose. More articles by this author Sam S. Chang Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee Financial interest and/or other relationship with Sanofi-Aventis, Tetralogic, Indevus, Bioniche and Amgen. More articles by this author Expand All Advertisement PDF downloadLoading ...